1 in 5 US Households Now Has a GLP-1 User as Stigma Still Shadows Weight-Loss Drugs
Updated
Updated · Vox.com · Aug 4
1 in 5 US Households Now Has a GLP-1 User as Stigma Still Shadows Weight-Loss Drugs
3 articles · Updated · Vox.com · Aug 4
Summary
One in five US households had at least one GLP-1 user by May 2026, even as many patients still hide their treatment or brace for judgment from family, coworkers and even clinicians.
More than 600 participants in a Rice-UCLA-Mayo study rated people who lost weight with GLP-1s more negatively than those who lost weight through diet and exercise — and even more negatively than people who never lost weight.
Survey data show the social pressure behind that tension: 81% of GLP-1 users said they felt pressure to be thin, 69% said others saw the drugs as a cheat code, and 43% avoided discussing their use for fear of judgment.
Researchers say the backlash reflects a persistent belief that weight is mainly about willpower, making medication look like an undeserved shortcut despite evidence that stigma can worsen mental health and deter care.
Access is expanding fast — Medicare began a $50 GLP-1 program in July and Eli Lilly says large-employer coverage rose to 67% from about 20% in 2025 — raising hopes wider use will gradually erode the stigma.